10x Genomics EV/EBITDA
What is the EV/EBITDA of 10x Genomics?
The EV/EBITDA of 10x Genomics, Inc. is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on NASDAQ compared to 10x Genomics
What does 10x Genomics do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Companies with ev/ebitda similar to 10x Genomics
- Bold Capital Enterprises has EV/EBITDA of N/A
- Gabriel Resources has EV/EBITDA of N/A
- GT Gold has EV/EBITDA of N/A
- Allied Copper has EV/EBITDA of N/A
- Dharani Sugars and Chemicals has EV/EBITDA of N/A
- Cleantek Industries Inc has EV/EBITDA of N/A
- 10x Genomics has EV/EBITDA of N/A
- Rigel Pharmaceuticals has EV/EBITDA of N/A
- Spark Power has EV/EBITDA of N/A
- Syrah Resources has EV/EBITDA of N/A
- The Motor & General Finance has EV/EBITDA of N/A
- Bernard Krief Consultants SA has EV/EBITDA of N/A
- Vimy Resources has EV/EBITDA of N/A